Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

As Philips stares down an international recall of more than 2 million of its CPAP and sleep apnea machines, the respiratory devicemaker ResMed is looking to pick up the slack—but the surge in demand ...

With Q3 behind us, let’s have a look at ResMed (NYSE:RMD) and its peers. Patient monitoring companies within the healthcare ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...

Alphabet subsidiary Verily is teaming up with well-known sleep company ResMed to form a new venture that will focus on developing sleep apnea treatments and connected health products. The latest ...

Loud snoring at night. Pauses in breathing followed by gasps for air while you’re asleep. Excessive daytime fatigue. Frequent nodding off in front of the TV or even when behind the wheel of a car.

With the pedal firmly to the metal in its U.S. business—thanks in no small part to rival CPAP machine maker Philips’ ongoing recall—ResMed has begun looking beyond its home turf to extend that winning ...

The “unlimited demand” for ResMed’s sleep apnea machines has given the San Diego, CA-based company the capital to become involved in some heavy-duty M&A. ResMed said it had signed a definitive ...

(MENAFN- GetNews) Air Voel, a leader in sleep therapy solutions in Canada, is proud to introduce its latest range of ResMed CPAP machines, designed to help individuals suffering from sleep apnea ...

ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS ...